Table 3 Differences in treatment intensity and disease control in primary care and specialist management for 29,851 children aged 2–17 years with actively treated asthma from a nationwide cohort
Primary care (N = 23,987)a | Specialist care (N = 5864)a | |
|---|---|---|
ICS dose | ||
Below low | 5885 (25%) | 562 (9.6%) |
Low | 7793 (32%) | 1748 (30%) |
Moderate | 6778 (28%) | 2127 (36%) |
High | 3531 (15%) | 1427 (24%) |
Average daily exposed dose (mcg beclomethasone) | 231 (128, 385) | 334 (205, 468) |
Add-on therapies | ||
Long-acting beta2-agonists | 5139 (21%) | 1755 (30%) |
Long-acting antimuscarinics | 34 (0.1%) | 36 (0.6%) |
Leukotriene receptor antagonists | 4581 (19%) | 1858 (32%) |
Asthma control | ||
Annual SABA use | 200 (100, 300) | 200 (100, 420) |
High annual SABA useb | 3430 (14%) | 1320 (23%) |
Exacerbations | ||
Any exacerbation(s) | 999 (4.2%) | 1354 (23%) |
Moderate exacerbation(s) | 394 (1.6%) | 222 (3.8%) |
Severe exacerbation(s) | 610 (2.5%) | 1197 (20%) |
Near fatal exacerbation(s) | 29 (0.1%) | 35 (0.6%) |
GINA 2020 exacerbation criteria | 682 (2.8%) | 1228 (21%) |